GLP-1 is as hormone secreted by the brain and intestinal L-cell
when foods are ingested, and acts on many organs.

• • It acts on the hypothalamus of the brain and helps to anorexigenic by increase the satiety.
  • In the pancreas, it encourages glucose-dependent insulin secretion by help the b-cells.
  • It keeps the satiety for a long time with the reduction of gastric emptying by delay the gastrointestinal motility.
  • It induces the reduction of hepatic glucose production and plasma glucagon concentration.
  
• • Saxenda® is 97% similar to GLP-1, a physiological appetite regulator secreted in response to food ingestion.
  • GLP-1 is secreted from the brain and intestines and acts on the hypothalamus responsible for appetite control.
  • Reduces the energy intake by increasing satiety and by reducing hungry.
  • With this action mechanism, patients who use Saxenda® can feel satisfied even if food intake is reduced, and can lose weight.

Changes in body weight of patients those who using Saxenda®

Weight change in 56 weeks of clinical test for 3,731 patients

Waist Measurement

Patients treated with Saxenda® had a waist measurement reduction of 8.2 cm.

“Comparison of 5 6weeks clinical weight changes in Saxenda® and placebo users group”
In a 56-week study of 3,731 patients without diabetes and a BMI ≥30, or ≥27
with at least 1 comorbidity.

According to the NEJM study on the weight loss effect of Liraglutide, the effect of weight-loss shows in the 9 out of 10 people,

the 2 out of 3 people 5 % or more,
and the 1 out of 3 people 10% or more.

체중변화,
그 이상의 효과

normal
glycaemic status

• In a 56-week study of 3,731 patients without diabetes and a BMI ≥30, or ≥27
  with at least 1 comorbidity :
  In a subset of patients with obesity and pre-diabetes(elevated glucose)
  randomised to Saxenda (n=1528)

Patients in the pre-diabetic group were divided into two groups, one group treated with Saxenda® and the other group observed natural progress. In the group those who observed by natural progress, the diabetes occurred in 11% of the patients, whereas, in the Saxenda® injection group, diabetes occurred just only in 3%, and the result shows that there is 3 times reduction effect in the Saxenda® injection group. The rate that blood-sugar of pre-diabetic patients returned to normal blood-sugar reached approximately 69%.
Regardless BMI, Obesity, pre-diabetes patients experience weight loss, and improved blood sugar regulation. In addition to the improvement of diabetes rates, there are reduction effect of risk group for stroke, myocardial infarction, and cardiovascular death.

“ The Saxenda® proved cardiovascular stability because it showed a reduction effect of blood pressure of about 4 mm Hg in systolic blood pressure. ”

BLOOD PRESSURE

Saxenda provided significant reductions in blood pressure vs placebo.

“ By improving lipid levels, lowering bad cholesterol LDL levels and elevating good cholesterol HDL levels. ”

Goal Setting and Confirmation

Evaluate the effectiveness of Saxendarphen® after 23 weeks from using of maintenance dose.

Administration Plan

• Gradual dose increment can minimize the nausea feeling that can occur when starting the Saxenda® first.
• As the dose increases, the body adapts to the drug and reduces nausea.

Injection Method